Chronic urticaria: New management options

Paul A. Greenberger*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

Chronic urticaria is defined as episodic or daily hives lasting for at least 6 weeks and impairs quality of life. Two main subtypes include chronic idiopathic (spontaneous) urticaria and inducible (physical) urticaria, but some patients have urticarial vasculitis. "Autoimmune chronic urticaria" implies the presence of histamine releasing or mast cell activating autoantibodies to IgE or FcϵRI, the high affinity receptor on mast cells and basophils. In patients not readily controlled with labeled dosages of second generation H1 receptor antagonists (antihistamines), there is evidence for reduction of urticaria using up to 4 fold increases in labeled dosages. The biologic modifier, omalizumab, helps to reduce lesions of chronic urticaria within 1-2 weeks.

Original languageEnglish (US)
Article number31
JournalWorld Allergy Organization Journal
Volume7
Issue number1
DOIs
StatePublished - 2014

Keywords

  • Antihistamine
  • Chronic
  • H receptor
  • Immunosuppressive
  • Omalizumab
  • Urticaria
  • Vasculitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Chronic urticaria: New management options'. Together they form a unique fingerprint.

Cite this